Imaging Tumor-Targeting Bacteria Using 18F-Fluorodeoxysorbitol Positron Emission Tomography

Author:

Ordonez Alvaro A12,Saupe Falk3,Kasper Christoph A3,Turner Mitchell L12,Parveen Sadiya4,Flavahan Kelly12,Shin Hyunsoo12,Artemov Dmitri5,Ittig Simon J3,Jain Sanjay K125

Affiliation:

1. Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA

2. Department of Pediatrics, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA

3. T3 Pharmaceuticals AG , Allschwil , Switzerland

4. Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA

5. Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA

Abstract

Abstract Background Microbial-based cancer treatments are an emerging field, with multiple bacterial species evaluated in animal models and some advancing to clinical trials. Noninvasive bacteria-specific imaging approaches can potentially support the development and clinical translation of bacteria-based cancer treatments by assessing the tumor and off-target bacterial colonization. Methods 18F-Fluorodeoxysorbitol (18F-FDS) positron emission tomography (PET), a bacteria-specific imaging approach, was used to visualize an attenuated strain of Yersinia enterocolitica, currently in clinical trials as a microbial-based cancer treatment, in murine models of breast cancer. Results Y. enterocolitica demonstrated excellent 18F-FDS uptake in in vitro assays. Whole-body 18F-FDS PET demonstrated a significantly higher PET signal in tumors with Y. enterocolitica colonization compared to those not colonized, in murine models utilizing direct intratumor or intravenous administration of bacteria, which were confirmed using ex vivo gamma counting. Conversely, 18F-fluorodeoxyglucose (18F-FDG) PET signal was not different in Y. enterocolitica colonized versus uncolonized tumors. Conclusions Given that PET is widely used for the management of cancer patients, 18F-FDS PET could be utilized as a complementary approach supporting the development and clinical translation of Y. enterocolitica-based tumor-targeting bacterial therapeutics.

Funder

T3 Pharmaceuticals, AG

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Reference27 articles.

1. Aus der Sitzung der medicinischen Section vom 13 November 1867;Busch;Berl Klin Wochenschr,1868

2. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas;McCarthy;Iowa Orthop J,2006

3. Tumour-targeting bacteria engineered to fight cancer;Zhou;Nat Rev Cancer,2018

4. Engineering the perfect (bacterial) cancer therapy;Forbes;Nat Rev Cancer,2010

5. Bacteriocins as potential anticancer agents;Kaur;Front Pharmacol,2015

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3